Hippocampus-related cognitive impairments in young apoE4 targeted replacement mice

Neurodegenerative Diseases

Volumn 13, Issue 2-3, 2014, Pages 86-92

  Salomon Zimri, Shiran ^a   Boehm Cagan, Anat ^a   Liraz, Ori ^a   Michaelson, Daniel M ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

Alzheimer's disease; Apolipoprotein E4; Behavior; Fear conditioning; Hippocampus; Morris water maze; Object recognition; Targeted replacement mice

Indexed keywords

APOLIPOPROTEIN E4; AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E3; TAU PROTEIN;

ALZHEIMER DISEASE; AMYGDALOID NUCLEUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COGNITIVE DEFECT; CONDITIONING; CONTROLLED STUDY; FEAR; GENETIC RISK; HIPPOCAMPUS; LEARNING; LIGHT-DARK TEST; MEMORY; MORRIS WATER MAZE TEST; MOUSE; NONHUMAN; NOVEL OBJECT RECOGNITION TEST; PRIORITY JOURNAL; STRESS; TASK PERFORMANCE; ANXIETY; CONFERENCE PAPER; GENOTYPE; HISTOLOGY; LOCOMOTION; LONG TERM MEMORY; NERVE CELL; NEUROPATHOLOGY; RECOGNITION; SHORT TERM MEMORY; SPATIAL LEARNING;

AGING; ALZHEIMER DISEASE; ANIMALS; APOLIPOPROTEIN E4; COGNITION DISORDERS; DISEASE MODELS, ANIMAL; HIPPOCAMPUS; HUMANS; LEARNING; MEMORY; MICE; MICE, INBRED C57BL;

EID: 84896855511     PISSN: 16602854     EISSN: 16602862     Source Type: Journal    
DOI: 10.1159/000354777     Document Type: Article

References (48)

1. Alzheimer A, Stelzmann RA, Schnitzlein HN, Murtagh FR: An English translation of Alzheimer's 1907 paper, 'Über eine eigenartige Erkankung der Hirnrinde'. Clin Anat 1995; 8: 429-431.
2. Tesseur I, Zou K, Esposito L, Bard F, Berber E, Can JV, Lin AH, Crews L, Tremblay P, Mathews P, Mucke L, Masliah E, Wyss-Coray T: Deficiency in neuronal TGF-beta signaling promotes neurodegeneration and Alzheimer's pathology. J Clin Invest 2006; 116: 3060-3069.
3. Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K: Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci USA 1985; 82: 4245-4249.
4. Glenner GG, Wong CW: Alzheimer's disease and Down's syndrome: sharing of a unique cerebrovascular amyloid fibril protein. Biochem Biophys Res Commun 1984; 122: 1131-1135.
5. Lee VM, Goedert M, Trojanowski JQ: Neurodegenerative tauopathies. Annu Rev Neurosci 2001; 24: 1121-1159.
6. Mandelkow EM, Stamer K, Vogel R, Thies E, Mandelkow E: Clogging of axons by tau, inhibition of axonal traffic and starvation of synapses. Neurobiol Aging 2003; 24: 1079-1085.
7. Buee L, Bussiere T, Buee-Scherrer V, Delacourte A, Hof PR: Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res Brain Res Rev 2000; 33: 95-130.
8. Inbar D, Belinson H, Rosenman H, Michaelson DM: Possible role of tau in mediating pathological effects of apoE4 in vivo prior to and following activation of the amyloid cascade. Neurodegener Dis 2010; 7: 16-23.
9. Conforti L, Adalbert R, Coleman MP: Neuronal death: where does the end begin? Trends Neurosci 2007; 30: 159-166.
10. Masliah E: Mechanisms of synaptic pathology in Alzheimer's disease. J Neural Transm Suppl 1998; 53: 147-158.
11. Scheff SW, DeKosky ST, Price DA: Quantitative assessment of cortical synaptic density in Alzheimer's disease. Neurobiol Aging 1990; 11: 29-37.
12. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA: Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993; 261: 921-923.
13. Roses AD: Apolipoprotein E alleles as risk factors in Alzheimer's disease. Annu Rev Med 1996; 47: 387-400.
14. Saunders AM, Strittmatter WJ, Schmechel D, George-Hyslop PH, Pericak-Vance MA, Joo SH, Rosi BL, Gusella JF, Crapper-MacLachlan DR, Alberts MJ, et al: Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. Neurology 1993; 43: 1467-1472.
15. Mori E, Lee K, Yasuda M, Hashimoto M, Kazui H, Hirono N, Matsui M: Accelerated hippocampal atrophy in Alzheimer's disease with apolipoprotein E epsilon4 allele. Ann Neurol 2002; 51: 209-214.
16. Schmechel DE, Saunders AM, Strittmatter WJ, Crain BJ, Hulette CM, Joo SH, Pericak-Vance MA, Goldgaber D, Roses AD: Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc Natl Acad Sci USA 1993; 90: 9649-9653.
17. Strittmatter WJ, Saunders AM, Goedert M, Weisgraber KH, Dong LM, Jakes R, Huang DY, Pericak-Vance M, Schmechel D, Roses AD: Isoform-specific interactions of apolipoprotein E with microtubule-associated protein tau: implications for Alzheimer disease. Proc Natl Acad Sci USA 1994; 91: 11183-11186.
18. Sunderland T, Mirza N, Putnam KT, Linker G, Bhupali D, Durham R, Soares H, Kimmel L, Friedman D, Bergeson J, Csako G, Levy JA, Bartko JJ, Cohen RM: Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele. Biol Psychiatry 2004; 56: 670-676.
19. Arendt T, Schindler C, Bruckner MK, Eschrich K, Bigl V, Zedlick D, Marcova L: Plastic neuronal remodeling is impaired in patients with Alzheimer's disease carrying apolipoprotein epsilon 4 allele. J Neurosci 1997; 17: 516-529.
20. Egensperger R, Kosel S, von Eitzen U, Graeber MB: Microglial activation in Alzheimer disease: association with APOE genotype. Brain Pathol 1998; 8: 439-447.
21. Reiman EM, Chen K, Liu X, Bandy D, Yu M, Lee W, Ayutyanont N, Keppler J, Reeder SA, Langbaum JB, Alexander GE, Klunk WE, Mathis CA, Price JC, Aizenstein HJ, DeKosky ST, Caselli RJ: Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. Proc Natl Acad Sci USA 2009; 106: 6820-6825.
22. Heise V, Filippini N, Ebmeier KP, Mackay CE: The APOE epsilon4 allele modulates brain white matter integrity in healthy adults. Mol Psychiatry 2010; 16: 908-916.
23. Liraz O, Boehm-Cagan A, Michaelson DM: ApoE4 induces Abeta42, tau, and neuronal pathology in the hippocampus of young targeted replacement apoE4 mice. Mol Neurodegener 2013; 8: 16.
24. Sullivan PM, Mezdour H, Aratani Y, Knouff C, Najib J, Reddick RL, Quarfordt SH, Maeda N: Targeted replacement of the mouse apolipoprotein E gene with the common human APOE3 allele enhances diet-induced hypercholesterolemia and atherosclerosis. J Biol Chem 1997; 272: 17972-17980.
25. Levi O, Jongen-Relo AL, Feldon J, Roses AD, Michaelson DM: ApoE4 impairs hippocampal plasticity isoform-specifically and blocks the environmental stimulation of synaptogenesis and memory. Neurobiol Dis 2003; 13: 273-282.
26. Belinson H, Michaelson DM: ApoE4-dependent Abeta-mediated neurodegeneration is associated with inflammatory activation in the hippocampus but not the septum. J Neural Transm 2009; 116: 1427-1434.
27. Bryan KJ, Lee H, Perry G, Smith MA, Casadesus G: Transgenic mouse models of Alzheimer's disease: behavioral testing and considerations; in Buccafusco JJ (ed): Methods of Behavioral Analysis in Neuroscience. Boca Raton, Taylor and Francis, 2009, pp 1-18.
28. Prado VF, Martins-Silva C, de Castro BM, Lima RF, Barros DM, Amaral E, Ramsey AJ, Sotnikova TD, Ramirez MR, Kim HG, Rossato JI, Koenen J, Quan H, Cota VR, Moraes MF, Gomez MV, Guatimosim C, Wetsel WC, Kushmerick C, Pereira GS, Gainetdinov RR, Izquierdo I, Caron MG, Prado MA: Mice deficient for the vesicular acetylcholine transporter are myasthenic and have deficits in object and social recognition. Neuron 2006; 51: 601-612.
29. Phillips RG, LeDoux JE: Differential contribution of amygdala and hippocampus to cued and contextual fear conditioning. Behav Neurosci 1992; 106: 274-285.
30. Segev Y, Michaelson DM, Rosenblum K: ApoE epsilon4 is associated with eIF2alpha phosphorylation and impaired learning in young mice. Neurobiol Aging 2013; 34: 863-872.
31. Olsen RH, Agam M, Davis MJ, Raber J: ApoE isoform-dependent deficits in extinction of contextual fear conditioning. Genes Brain Behav 2012; 11: 806-812.
32. Kornecook TJ, McKinney AP, Ferguson MT, Dodart JC: Isoform-specific effects of apolipoprotein E on cognitive performance in targeted-replacement mice overexpressing human APP. Genes Brain Behav 2010; 9: 182-192.
33. Fitz NF, Cronican AA, Lefterov I, Koldamova R: RXR agonist bexarotene restores memory deficits but does not affect Aβ plaques in APP/PS1 mice expressing human APO isoforms. AD/PD conference, Florence, 2013.
34. Veinbergs I, Mallory M, Mante M, Rockenstein E, Gilbert JR, Masliah E: Differential neurotrophic effects of apolipoprotein E in aged transgenic mice. Neurosci Lett 1999; 265: 218-222.
35. Yin JX, Turner GH, Lin HJ, Coons SW, Shi J: Deficits in spatial learning and memory is associated with hippocampal volume loss in aged apolipoprotein E4 mice. J Alzheimers Dis 2011; 27: 89-98.
36. Raber J, Wong D, Buttini M, Orth M, Bellosta S, Pitas RE, Mahley RW, Mucke L: Isoformspecific effects of human apolipoprotein E on brain function revealed in ApoE knockout mice: increased susceptibility of females. Proc Natl Acad Sci USA 1998; 95: 10914-10919.
37. Grootendorst J, Bour A, Vogel E, Kelche C, Sullivan PM, Dodart JC, Bales K, Mathis C: Human apoE targeted replacement mouse lines: h-apoE4 and h-apoE3 mice differ on spatial memory performance and avoidance behavior. Behav Brain Res 2005; 159: 1-14.
38. Anagnostaras SG, Maren S, Fanselow MS: Temporally graded retrograde amnesia of contextual fear after hippocampal damage in rats: within-subjects examination. J Neurosci 1999; 19: 1106-1114.
39. LeDoux JE, Cicchetti P, Xagoraris A, Romanski LM: The lateral amygdaloid nucleus: sensory interface of the amygdala in fear conditioning. J Neurosci 1990; 10: 1062-1069.
40. Fitz NF, Cronican AA, Saleem M, Fauq AH, Chapman R, Lefterov I, Koldamova R: Abca1 deficiency affects Alzheimer's disease-like phenotype in human ApoE4 but not in ApoE3-targeted replacement mice. J Neurosci 2012; 32: 13125-13136.
41. Nichol K, Deeny SP, Seif J, Camaclang K, Cotman CW: Exercise improves cognition and hippocampal plasticity in APOE epsilon4 mice. Alzheimers Dement 2009; 5: 287-294.
42. Berteau-Pavy F, Park B, Raber J: Effects of sex and APOE epsilon4 on object recognition and spatial navigation in the elderly. Neuroscience 2007; 147: 6-17.
43. Hartman RE, Wozniak DF, Nardi A, Olney JW, Sartorius L, Holtzman DM: Behavioral phenotyping of GFAP-apoE3 and-apoE4 transgenic mice: apoE4 mice show profound working memory impairments in the absence of Alzheimer's-like neuropathology. Exp Neurol 2001; 170: 326-344.
44. van Meer P, Acevedo S, Raber J: Impairments in spatial memory retention of GFAP-apoE4 female mice. Behav Brain Res 2007; 176: 372-375.
45. Laczo J, Andel R, Vlcek K, Macoska V, Vyhnalek M, Tolar M, Bojar M, Hort J: Spatial navigation and APOE in amnestic mild cognitive impairment. Neurodegener Dis 2011; 8: 169-177.
46. Laczo J, Andel R, Vyhnalek M, Vlcek K, Magerova H, Varjassyova A, Tolar M, Hort J: Human analogue of the Morris water maze for testing subjects at risk of Alzheimer's disease. Neurodegener Dis 2010; 7: 148-152.
47. Kesner RP: Functional specificity of memory function associated with different subregions of the medial temporal lobe. Curr Neurol Neurosci Rep 2003; 3: 449-451.
48. Olton DS, Walker JA, Gage FH: Hippocampal connections and spatial discrimination. Brain Res 1978; 139: 295-308.